[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Sakamoto H, Oohta M, Inoue K, Fuji K, Fukagai T, Yoshida H: Testicular sperm extraction in patients with persistent azoospermia after chemotherapy for testicular germ cell tumor. Int J Urol; 2007 Feb;14(2):167-70
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular sperm extraction in patients with persistent azoospermia after chemotherapy for testicular germ cell tumor.
  • Sperm cryopreservation before chemotherapy in young males is recommended because of chemotherapy's gonadotoxic effects.
  • Two azoospermic patients presented to us after chemotherapy, and we obtained sperm from them by testicular sperm extraction (TESE).
  • One patient was 32 years old and had been treated with six cycles of cisplatin, etoposide and bleomycin (BEP) chemotherapy and one cycle of high-dose chemotherapy for stage III non-seminoma.
  • Histopathology of the testicular specimen showed germinal aplasia with focal islands of full spermatogenesis.
  • The other patient was 33 years old who was treated with four cycles of BEP chemotherapy for stage II seminoma.
  • Histopathology of the testicular specimen showed Sertoli-cell-only syndrome.
  • TESE should be considered in patients with persistent azoospermia after chemotherapy if frozen sperm samples are not available.
  • [MeSH-major] Azoospermia / etiology. Neoplasms, Germ Cell and Embryonal / drug therapy. Spermatozoa. Testicular Neoplasms / drug therapy. Tissue and Organ Harvesting

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17302578.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


2. Schrader M, Muller M, Straub B, Miller K: Testicular sperm extraction in azoospermic patients with gonadal germ cell tumors prior to chemotherapy--a new therapy option. Asian J Androl; 2002 Mar;4(1):9-15
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular sperm extraction in azoospermic patients with gonadal germ cell tumors prior to chemotherapy--a new therapy option.
  • BACKGROUND: In view of the high cure rates in patients with testicular germ cell tumors (TGCT), increasing clinical importance is attached to protection of fertility.
  • Long-term infertility due to cytostatic therapy may be expected in more than 50% of the patients at a cumulative dose of cisplatin > 0.6 g/m2.
  • The standard procedure for fertility protection in cancer patients includes cryopreservation of ejaculated spermatozoa.
  • Considering that some patients have tumor-induced azoospermia, we examined the usefulness of testicular sperm extraction before therapy.
  • METHOD: A survey of the literature served as a basis for investigating biological and clinical aspects of the impact of chemotherapy on male fertility.
  • A study of our patient population also enabled us to explore the option of extracting sperm from the contralateral healthy testis prior to treatment in 14 azoospermic patients with testicular germ cell tumors.
  • RESULTS: We were able to successfully recover haploid germ cells in 6/14 testicular biopsies from azoospermic patients with testicular germ cell cancer prior to treatment.
  • Maturation arrest was found in 3/14 cases and Sertoli-cell-only syndrome in the rest.
  • None of the patients had secondary healing or a treatment delay because of the testicular biopsy.
  • CONCLUSION: Since the post-therapeutic fertility status is difficult to predict in cancer patients, we think that TESE should be regarded as a general option prior to cancer treatment and offered to azoospermic cancer patients.
  • [MeSH-major] Germinoma / pathology. Infertility, Male / therapy. Oligospermia / pathology. Spermatozoa / cytology. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Male Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11907623.001).
  • [ISSN] 1008-682X
  • [Journal-full-title] Asian journal of andrology
  • [ISO-abbreviation] Asian J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 54
  •  go-up   go-down


3. Sassa N, Yoshino Y, Matsukawa Y, Komatsu T, Yoshikawa Y, Yamamoto T, Hattori R, Gotoh M: [Case report of malignant sertoli cell tumor]. Nihon Hinyokika Gakkai Zasshi; 2008 Jul;99(5):656-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case report of malignant sertoli cell tumor].
  • Malignant sertoli cell tumor is a rare disease and only a few cases have been described previously.
  • We report a terminal case of malignant sertoli cell tumor.
  • A 38-year-old male visited a hospital with a complaint of swelling his left testis.
  • His pathologic diagnosis was suspected seminoma, and all tumor markers (LDH, HCG, AFP) were negative, and CT imaging confirmed clinical stage 1 (pT1N0M0S0).
  • He received 3 courses of chemotherapy with BEP (bleomycine, etoposide, cisplatin), but, lymph node size did not change.
  • After he underwent a CT guided lymph node biopsy, his pathologic diagnosis was viable embryonal carcinoma.
  • We selected CPT-11 and nedaplatin for his salvage chemotherapy, but lymph node lesions did not change.
  • After he received 3 courses of chemotherapy, we performed retroperitoneal lymphadenectomy.
  • His pathologic diagnosis was viable sertoli cell tumor, malignant type.
  • All tumor markers were negative in his all clinical courses.
  • [MeSH-major] Sertoli Cell Tumor / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Fatal Outcome. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Orchiectomy. Organoplatinum Compounds / administration & dosage. Salvage Therapy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697473.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Organoplatinum Compounds; 7673326042 / irinotecan; 8UQ3W6JXAN / nedaplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


Advertisement
4. Talon I, Moog R, Kauffmann I, Grandadam S, Becmeur F: Sertoli cell tumor of the testis in children: reevaluation of a rarely encountered tumor. J Pediatr Hematol Oncol; 2005 Sep;27(9):491-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli cell tumor of the testis in children: reevaluation of a rarely encountered tumor.
  • Testis tumors are uncommon in childhood, and they differ from adult tumors in terms of histology and frequency.
  • Sertoli cell tumors appear in children before 1 year of age.
  • They are more frequently benign, but because of the absence of specific signs of malignancy, treatment consists of radical orchiectomy, sometimes followed by radiotherapy or chemotherapy based on histologic analysis.
  • In the authors' hospital, of 13 testis tumors diagnosed since 1996, only 2 were Sertoli cell tumors.
  • It would be helpful to have an algorithm for the management of testis tumors, outlining how to make the diagnosis of malignancy and which treatment and follow-up to pursue.
  • [MeSH-major] Algorithms. Sertoli Cell Tumor / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Age Factors. Child, Preschool. Humans. Infant. Male. Neoplasm Staging. Orchiectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16189443.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Hummel M, Schaaf L, Füchtenbusch M, Standl E, Ziegler A: [62 year-old patient with rapid progressive edema, low potassium and hypertension]. Internist (Berl); 2006 Apr;47(4):427, 429-33
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary neoplasm is a small cell cancer.
  • A Sertoli-cell-tumor of the testis was diagnosed as an additional carcinoma.
  • Palliative chemotherapy and adrenostatic agents did not improve the clinical findings and the patient died eight weeks after admission.
  • [MeSH-major] Cushing Syndrome / etiology. Edema / etiology. Hypertension / etiology. Hypokalemia / etiology. Sertoli Cell Tumor / complications. Testicular Neoplasms / complications. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):129-31 [8769407.001]
  • [Cites] J Endocrinol Invest. 2002 Apr;25(4):369-72 [12030610.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1361-7 [8111702.001]
  • [Cites] Nuklearmedizin. 2002 Apr;41(2):80-90 [11989302.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Apr;84(4):1193-202 [10199752.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Apr;84(4):1186-92 [10199751.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Aug;89(8):3752-63 [15292301.001]
  • [Cites] J Steroid Biochem Mol Biol. 1992 Oct;43(5):403-8 [1327073.001]
  • [Cites] Dtsch Med Wochenschr. 1992 Oct 16;117(42):1605-10 [1327711.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Oct;61(4):478-86 [15473881.001]
  • [Cites] J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):403-8 [10419018.001]
  • [Cites] J Steroid Biochem Mol Biol. 1994 Jun;49(4-6):261-7 [8043488.001]
  • (PMID = 16470359.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Ray-Coquard I, Pautier P, Pujade-Lauraine E, Méeus P, Morice P, Treilleux I, Duvillard P, Alexandre J, Lhommé C, Selle F, Guastalla J: [Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers in France]. Bull Cancer; 2010 Jan;97(1):123-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers in France].
  • [Transliterated title] Les tumeurs rares de l'ovaire: stratégies thérapeutiques en 2010, Observatoire francophone des tumeurs rares de l'ovaire et émergence des centres de références.
  • Majorities of the rare ovarian cancers were represented by germ cell tumours and sex cords ovarian tumours with borderline tumours, clear cell carcinoma and mucinous carcinoma and are extremely rare malignant diseases of the ovaries.
  • Tumors of the stromal (Leydig cells) and/or sex cords (Sertoli cells) represent approximately 7% of ovarian cancers and develop from the conjunctive tissue (respectively, interstitial and nurse cells) of the ovaries.
  • Treatment of rare ovarian tumors is currently as follows.
  • Surgery is the same as that for ovarian adenocarcinoma, with one major difference: conservation of reproductive function in women of reproductive age is usual case for this type of tumor.
  • Chemotherapy for germ cell and sex cords tumors, based on data reported in the literature is the same as that prescribed for testicular germ-cell tumors.
  • For rare epithelial carcinoma, carboplatin plus paclitaxel remains the standard attitude with a well-known less efficiency than for other epithelial subtypes.
  • Surgery, chemotherapy and possible surgical intervention for residual lesions are highly complex.
  • Too rare to be included in randomized studies, treatment of these tumors has benefited from the therapeutic advancements made against testicular germ-cell tumors or with publications using retrospective data.
  • Because of the rarity of these tumours a specialized website (www.ovaire-rare.org) was developed in France in 2002.
  • The website provides very interesting data for a better knowledge of these rare tumors and will possibly help improve medical practice.
  • Since 2008, referent centers were delineated to promote optimal management of these tumors, organization of clinical and molecular research at a national or international level and to elaborate guidelines.
  • The other new scientific data concern surgical procedures for sex cords tumors, evidence for presence of FOXL2 mutation in adult granulosa cell tumors, the use of paclitaxel plus carboplatin for sex cords tumors.
  • [MeSH-major] Cancer Care Facilities / organization & administration. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / therapy. Adult. Antineoplastic Agents / therapeutic use. Female. France. Humans. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / therapy. Rare Diseases / pathology. Rare Diseases / therapy. Sarcoma / pathology. Sarcoma / therapy. Sex Cord-Gonadal Stromal Tumors / pathology. Sex Cord-Gonadal Stromal Tumors / therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20007069.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Lefevre H, Bouvattier C, Lahlou N, Adamsbaum C, Bougnères P, Carel JC: Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor. Eur J Endocrinol; 2006 Feb;154(2):221-7
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Peutz-Jeghers syndrome (PJS) is a rare autosomal-dominant disorder characterized by multiple gastrointestinal hamartomatous polyps, mucocutaneous pigmentation and increased predisposition to various neoplasms.
  • Endocrine manifestations in PJS include gynecomastia due to calcified Sertoli cell testicular tumors usually referred to as large-cell calcifying Sertoli cell tumors (LSCT).
  • OBJECTIVE: To evaluate the value of endocrine markers and aromatase inhibitor treatment in children with PJS and LSCT.
  • MAIN OUTCOME MEASURES: Longitudinal measurements of sex-steroids, gonadotropins, Sertoli cell markers and auxological evaluation.
  • RESULTS: The two male siblings with PJS had similar bilateral multifocal testicular calcifications and biochemical evidence of Sertoli cell dysfunction manifested by elevated plasma inhibin-alpha levels.
  • During treatment with anastrozole, estradiol levels, growth and skeletal maturation, as well as Sertoli cell markers (inhibin B, inhibin-alpha and anti-Mullerian hormone) decreased.
  • Moreover, the decrease in Sertoli cell markers during aromatase inhibitor treatment suggests that increased estrogen production is a primary event regulating downstream production of Sertoli cell peptides.

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452534.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Glycoproteins; 0 / Nitriles; 0 / Testicular Hormones; 0 / Triazoles; 0 / inhibin B; 0 / inhibin-alpha subunit; 2Z07MYW1AZ / anastrozole; 57285-09-3 / Inhibins; 80497-65-0 / Anti-Mullerian Hormone; 9007-49-2 / DNA
  •  go-up   go-down


8. Mosharafa AA, Foster RS, Bihrle R, Koch MO, Ulbright TM, Einhorn LH, Donohue JP: Does retroperitoneal lymph node dissection have a curative role for patients with sex cord-stromal testicular tumors? Cancer; 2003 Aug 15;98(4):753-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does retroperitoneal lymph node dissection have a curative role for patients with sex cord-stromal testicular tumors?
  • BACKGROUND: Sex cord-stromal tumors account for < 5% of all adult testicular tumors, and 10% are malignant.
  • Due to the limited reported experience, there is no agreement on the best management, especially in patients who have tumors with malignant pathologic features or who present with metastatic disease.
  • The authors attempt to evaluate the role of retroperitoneal lymph node dissection (RPLND) in the management of patients with these malignant sex cord-stromal tumors.
  • METHODS: Reviewing the Indiana University testis cancer registry revealed 17 patients who underwent RPLND for sex cord-stromal tumors.
  • The data examined included clinical and pathologic stage, surgical procedure, additional therapy received, and outcome.
  • RESULTS: Pathology included Leydig tumors in six patients, Sertoli tumors in four patients, sex cord-stromal tumors in five patients, a granulosa cell tumor in one patient, and a poorly differentiated non-germ cell tumor in one patient.
  • Nine patients had pathologic Stage I tumors, and the remaining eight patients and had pathologic Stage IIB-IIIA tumors.
  • Of the eight patients with Stage II-III disease, six patients eventually died of metastatic disease despite additional radiotherapy and/or chemotherapy.
  • CONCLUSIONS: Sex cord-stromal tumors have a potentially aggressive malignant behavior that is difficult to predict based on clinical and pathologic features.
  • Although the therapeutic role of RPLND in patients with small-volume metastatic retroperitoneal tumors is unclear, RPLND remains an option to be performed immediately after orchiectomy, especially in patients who have tumors with malignant features and/or small-volume metastatic disease.
  • [MeSH-major] Lymph Node Excision. Sex Cord-Gonadal Stromal Tumors / surgery. Testicular Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12910519.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Schrader M, Müller M, Sofikitis N, Straub B, Krause H, Miller K: "Onco-tese": testicular sperm extraction in azoospermic cancer patients before chemotherapy-new guidelines? Urology; 2003 Feb;61(2):421-5
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Onco-tese": testicular sperm extraction in azoospermic cancer patients before chemotherapy-new guidelines?
  • OBJECTIVES: To examine the usefulness of pretreatment testicular sperm extraction because some patients have tumor-induced azoospermia.
  • In view of the high cure rates for testicular germ cell tumors and malignant lymphomas, increasing clinical importance is attached to protecting fertility.
  • High-dose cytostatic therapy may be expected to cause long-term infertility.
  • Thus, the standard procedure for fertility protection is cryopreservation of ejaculated spermatozoa before therapy.
  • METHODS: Contralateral testicular biopsies were taken from 14 azoospermic patients with malignant testicular germ cell tumors.
  • In addition, 17 patients with malignant lymphomas underwent unilateral (n = 6) or bilateral (n = 11) testicular biopsy.
  • The tissue specimens were cryopreserved, and the histologic workup was performed at the same time.
  • RESULTS: Of the 14 patients with malignant testicular germ cell tumors, 6 had spermatozoa in their testicular biopsies.
  • Sertoli cell-only syndrome was found in 5 patients, and 3 had maturation arrest without detection of spermatozoa.
  • Successful sperm recovery was possible in 8 of the 17 patients with malignant lymphoma, 4 had Sertoli cell-only syndrome, and 5 had maturation arrest.
  • None of the patients had evidence of secondary wound healing or treatment delay because of the testicular biopsy.
  • CONCLUSIONS: Our results show that testicular sperm extraction is a useful technique for obtaining spermatozoa before cytotoxic therapy in azoospermic cancer patients.
  • This procedure should be considered as an option for fertility preservation in azoospermic cancer patients, because high cumulative cytostatic doses can cause irreversible fertility alterations.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Germinoma / drug therapy. Oligospermia / chemically induced. Spermatozoa / physiology. Testicular Neoplasms / drug therapy. Testis / surgery. Tissue and Organ Harvesting / methods
  • [MeSH-minor] Biopsy, Needle. Cryopreservation / methods. Humans. Lymphoma / pathology. Male. Sertoli Cell Tumor / drug therapy. Sertoli Cell Tumor / pathology. Sperm Count

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12597960.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Fleckenstein GH, Gunawan B, Brinck U, Wuttke W, Emons G: Simultaneous sertoli cell tumor and adenocarcinoma of the tunica vaginalis testis in a patient with testicular feminization. Gynecol Oncol; 2002 Mar;84(3):460-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous sertoli cell tumor and adenocarcinoma of the tunica vaginalis testis in a patient with testicular feminization.
  • BACKGROUND: The association of testicular feminization with late diagnosis in a patient with a large Sertoli cell tumor and a metastasizing adenocarcinoma of the tunica vaginalis testis is unusual.
  • CASE: Testicular feminization was diagnosed in a 72-year-old patient, who was admitted with a large lower abdominal mass.
  • Histologically, we found a well-differentiated Sertoli cell tumor and an adenocarcinoma of the tunica vaginalis testis with metastases in the sigmoid colon, rectum, and omentum.
  • Explorative laparotomy revealed a large pelvic tumor mass and extensive peritoneal carcinosis.
  • After debulking surgery to optimal residual disease and four courses of chemotherapy (cisplatin and etoposide), there was no evidence of disease (clinically) for 24 months before an intraabdominal and inguinal relapse occurred.
  • Due to the unwillingness of the patient to receive salvage chemotherapy or palliative abdominal surgery, the disease progressed rapidly and she died 27 months after the initial operation.
  • CONCLUSION: This is the first reported case of an advanced carcinoma of the tunica vaginalis testis occurring simultaneously with a large Sertoli cell tumor in a patient with testicular feminization.
  • Surgical debulking and platinum-based chemotherapy rendered the patient clinically free of disease for 2 years.
  • [MeSH-major] Adenocarcinoma / pathology. Androgen-Insensitivity Syndrome / pathology. Sertoli Cell Tumor / pathology. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Testicular Feminization.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11855889.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Gurariĭ LL, Volkova MI, Khalaf'ian EA, Zakharova TI: [Testicular sertolioma]. Urologiia; 2002 Jul-Aug;(4):10-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular sertolioma].
  • Sertolioma accounts for 4.5% of all non-herminogenic testicular tumors.
  • Sertolioma presents clinically with local symptoms (enlarged testis) which may be associated with dyshormonal symptoms.
  • The treatment should be started with orchofuniculectomy.
  • Surgical treatment is the only treatment effective in malignant sertolioma.
  • Sertolioma is resistant to chemotherapy and is low sensitive to radiotherapy.
  • [MeSH-major] Sertoli Cell Tumor / diagnosis. Testicular Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12357891.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


12. Chan PT, Palermo GD, Veeck LL, Rosenwaks Z, Schlegel PN: Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy. Cancer; 2001 Sep 15;92(6):1632-7
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy.
  • BACKGROUND: Men who remain azoospermic long after undergoing chemotherapy have generally been considered sterile.
  • The authors report their experience with testicular sperm extraction (TESE) combined with intracytoplasmic sperm injection (ICSI) applied to azoospermic men who previously received chemotherapy for a variety of indications.
  • METHODS: Among 231 cycles in 198 patients who underwent TESE-ICSI for nonobstructive azoospermia from 1995 to 2000, 20 TESE procedures in 17 patients who previously received chemotherapy were identified.
  • The pretreatment hormonal profile, histology of testicular biopsies, and outcomes of TESE-ICSI in this subgroup of patients were analyzed.
  • Six patients had received chemotherapy for Hodgkin lymphoma (34%), four patients had received chemotherapy for testicular neoplasm (24%), two patients had received chemotherapy for non-Hodgkin lymphoma (12%), two patients had received chemotherapy for leukemia (12%), one patient had received chemotherapy for Wilms tumor (6%), one patient had received chemotherapy for mediastinal germ cell tumor (6%), and one patient had received chemotherapy for nephrotic syndrome (6%).
  • Three patients (18%) received additional radiation therapy.
  • The mean interval from chemotherapy to TESE was 16.3 years (range, 6-34 years).
  • Testicular histology revealed Sertoli cell-only pattern in 76% of patients.
  • Among the men with Sertoli cell-only pattern, 23% had sperm retrieved by TESE.
  • No correlation was noted between the outcome of TESE-ICSI and the underlying conditions that were treated with chemotherapy nor with the chemotherapeutic agents used.
  • CONCLUSIONS: Using TESE-ICSI, sperm retrieval leading to pregnancy and the delivery of healthy children is possible for men with long-standing azoospermia after chemotherapy.
  • The prognosis for sperm retrieval was not influenced clearly by the chemotherapy regimen or the disease treated.
  • Despite prolonged nonobstructive azoospermia after undergoing chemotherapy, men no longer should be considered sterile in the era of advanced assisted reproductive techniques.
  • [MeSH-major] Oligospermia / therapy. Reproductive Techniques, Assisted. Spermatozoa
  • [MeSH-minor] Adult. Cytoplasm. Female. Follicle Stimulating Hormone / analysis. Hodgkin Disease / drug therapy. Humans. Injections. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Pregnancy. Testis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Assisted Reproductive Technology.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11745242.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


13. Efstathiou E, Logothetis CJ: Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw; 2006 Nov;4(10):1059-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of late complications of treatment and late relapse in testicular cancer.
  • With testicular cancer, a disease with a cure rate of 95%, the challenge is to restore quality of life to pretreatment levels and sustain it long-term.
  • Although the implementation of guidelines and optimization of treatment modalities over the past years have served this purpose, some complications remain inevitable and experts are still challenged with late complications of outdated treatment standards.
  • This article focuses on the late complications of cisplatin-based chemotherapy without disregarding those of currently applied infradiaphragmatic radiation.
  • The most serious long-term complications of chemotherapy or radiotherapy are cardiovascular toxicity and second malignancies, as each has a 25-year risk of approximately 16%.
  • Compared with the general population, risk for second malignancies remains significantly increased for at least 35 years after treatment.
  • Chemotherapy-related cardiovascular toxicity is probably a result of both direct endothelial damage induced by cisplatin and indirect hormonal and metabolic changes.
  • Cisplatin-based chemotherapy affects not only Leydig cells but also Sertoli and germ cells, resulting in infertility in 30% to 50% of testicular cancer patients treated with chemotherapy.
  • Although current treatment of advanced disease has changed its natural course, we are challenged by an increasing incidence of late relapse, an entity with a distinct tumor biology characterized by latency and chemoresistance.
  • [MeSH-major] Neoplasm Recurrence, Local / diagnosis. Neoplasms, Second Primary / diagnosis. Testicular Neoplasms / pathology. Testicular Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Cisplatin / adverse effects. Cohort Studies. Humans. Male. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / therapy. Radiation Injuries / etiology. Time Factors

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17112453.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 101
  •  go-up   go-down


14. Nakano A, Yoshida M, Harada T, Araki A, Pineda L, Iijima M, Sezer C, Zhou L, Maruyama R: Intratubular germ cell neoplasia of unclassified type occupying the whole testis accompanied by a small mature teratoma and metastatic choriocarcinoma and Sertoli cell-only tubules in the other testis. Pathol Int; 2003 Oct;53(10):726-32
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratubular germ cell neoplasia of unclassified type occupying the whole testis accompanied by a small mature teratoma and metastatic choriocarcinoma and Sertoli cell-only tubules in the other testis.
  • A 19-year-old man with mild mental retardation was diagnosed as having metastatic choriocarcinoma and a testicular tumor.
  • Histopathological examination of the resected testis revealed the presence of a small lesion of mature teratoma but no trace of choriocarcinoma.
  • The remaining seminiferous tubules were atrophic and lined by large atypical germ cells, which were diagnosed as intratubular germ cell neoplasia of the unclassified type (IGCNU).
  • A small area with prominent tubules was also observed.
  • Within this lesion, the tubules were dilated and contained several layers of cells with central necrosis.
  • Immunohistological comparison of staining for several biological markers (Ki-67, c-kit and placental alkaline phosphatase) between cells in the atrophic tubules and those in the dilated tubules indicated a progression of the latter cells to cells with a more proliferative ability.
  • In the opposite testis, examined at autopsy after death due to metastatic choriocarcinoma, all seminiferous tubules were lined by Sertoli cells only.
  • It was therefore assumed that the germ cell tumor of the combined histological type had primarily arisen in the background of IGCNU, and that choriocarcinoma had spontaneously regressed.
  • The early onset of these testicular neoplastic lesions strongly indicates their occurrence under the genetic background of gonadal dysplasia, the Sertoli cell-only syndrome.
  • [MeSH-major] Choriocarcinoma, Non-gestational / secondary. Germinoma / pathology. Neoplasms, Multiple Primary / pathology. Seminiferous Tubules / pathology. Sertoli Cells / pathology. Teratoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Drug Therapy. Fatal Outcome. Humans. Immunohistochemistry. Male. Organ Size

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14516326.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


15. Cao Avellaneda E, Alarcón Martínez H, Fuster Soler JL, López Cubillana P, Llinares Riestra E, Pérez Albacete M: [Testicular and paratesticular prepuberal tumors: our experience and update on the topic]. Actas Urol Esp; 2005 Apr;29(4):355-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular and paratesticular prepuberal tumors: our experience and update on the topic].
  • [Transliterated title] Tumores testiculares y paratesticulares prepuberales. Experiencia en nuestro centro y revisión de la literatura.
  • OBJECTIVES: To evaluate the importance of testicular and paratesticular prepubertal tumors in our center and to make an update on the topic.
  • METHODS AND PATIENTS: Data from all patients diagnosed of testicular and paratesticular prepubertal tumors and treated in our pediatric oncology unit from January 1st 1998 to December 31st 2003 have been revised.
  • RESULTS: Seven cases are reported among one hundred and ninety patients (represents 3,68 percent of all treated tumors): five tumors affecting the testis and two cases of paratesticular tumors.
  • Pathology classification was as follows: one yolk sack tumor, one mature teratoma, two nongerminomatous testicular tumors (one Sertoli cell tumor and one unclassifiable), one Burkitt's lymphoma and two paratesticular rhabdomyosarcomas.
  • Primary approach was inguinal radical orchiectomy in all cases except neoadjuvant chemotherapy in the case of lymphoma and partial escrotectomy in one patient previously managed with transcrotal orchiectomy.
  • Rhabdomyosarcoma cases received adjuvant chemotherapy.
  • CONCLUSIONS: Testicular and paratesticular prepubertal tumors are rare.
  • Except for one patient affected of lymphoma, surgical primary approach have been essential for treatment.
  • [MeSH-major] Testicular Neoplasms / pathology
  • [MeSH-minor] Child. Humans. Infant. Male. Neoplasm Staging. Orchiectomy. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981422.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


16. Steffens J, Treiyer A, Calaminus G: [Management of pediatric testicular tumors : diagnosis, therapy, and follow-up]. Urologe A; 2009 Apr;48(4):359-63
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of pediatric testicular tumors : diagnosis, therapy, and follow-up].
  • [Transliterated title] Präpubertäre Hodentumoren : Diagnose, Therapie und Nachbeobachtung.
  • Based on findings from the Prepubertal Testis Tumor Registry by the Urologic Section of the American Academy of Pediatrics and collaborative data in the literature, a modern algorithm for the surgical management of prepubertal testis tumors is presented.
  • Following testicular surgery, patients with universally benign tumors, such as teratoma, may be released from oncological follow-up.
  • Children with stage I yolk sac tumors should be monitored closely with periodic AFP tumor marker evaluation and imaging according to the primary dissemination (e.g., ultrasound, chest x-ray, and computed tomography).
  • Patients with recurrent or metastatic yolk sac tumors should be treated with platinum-based chemotherapy and appropriate follow-up.
  • Retroperitoneal lymph node dissection is not recommended except for patients with residual retroperitoneal masses following chemotherapy.
  • Aggressive treatment is warranted for metastatic Sertoli cell and metastatic undifferentiated stromal tumors.
  • [MeSH-major] Medical Oncology / trends. Pediatrics / trends. Testicular Neoplasms / diagnosis. Testicular Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Children's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2412-5; discussion 2415-6 [14634440.001]
  • [Cites] J Urol. 2004 Aug;172(2):674-8 [15247758.001]
  • [Cites] J Pediatr Urol. 2007 Dec;3(6):480-3 [18947799.001]
  • [Cites] Klin Padiatr. 2002 Jul-Aug;214(4):167-72 [12165897.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 2):1675-8; discussion 1678-9 [12352332.001]
  • [Cites] J Urol. 2004 Jan;171(1):161-3 [14665867.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 2):671-4 [8392120.001]
  • [Cites] J Urol. 2004 Dec;172(6 Pt 1):2370-2 [15538270.001]
  • [Cites] Klin Padiatr. 1999 Jul-Aug;211(4):300-4 [10472566.001]
  • [Cites] J Urol. 2008 May;179(5):1961-5 [18355842.001]
  • [Cites] Ann Oncol. 2000 Mar;11(3):263-71 [10811491.001]
  • [Cites] J Urol. 2006 Aug;176(2):703-5 [16813923.001]
  • [Cites] Pediatr Hematol Oncol. 1998 Mar-Apr;15(2):135-42 [9592840.001]
  • [Cites] Urology. 2006 Aug;68(2):402-5; discussion 405 [16904461.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):309-14 [17080332.001]
  • [Cites] J Urol. 1995 Apr;153(4):1259-61 [7869524.001]
  • (PMID = 19280171.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 19
  •  go-up   go-down


17. Tröbs RB, Krauss M, Geyer C, Tannapfel A, Körholz D, Hirsch W: Surgery in infants and children with testicular and paratesticular tumours: a single centre experience over a 25-year-period. Klin Padiatr; 2007 May-Jun;219(3):146-51
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery in infants and children with testicular and paratesticular tumours: a single centre experience over a 25-year-period.
  • Testicular and even more paratesticular tumours in children are rare.
  • The aim of the study is to characterise the spectrum of these lesions with focus on the feasibility and effectiveness of testis sparing surgery.
  • The spectrum of testicular tumours comprised 13 germ cell tumours (6 yolk sac tumours, 6 teratomas, 1 embryonal carcinoma) and 4 sex cord stromal tumours (2 Leydig's cell, Sertoli's cell, granulosa cell).
  • Both Leydig's cell tumours were endocrine active.
  • Further on, we observed 3 boys with paratesticular rhabdomyosarcoma (RMS), and three with testicular and paratesticular metastases (Wilms' tumour, neuroblastoma, leukaemia).
  • Dependent on tumour histology, stage and the recommended treatment schedule postoperative chemotherapy was added.
  • Testis sparing surgery was performed in 3 boys with primary testicular tumours (2 Leydig's cell, mature cystic teratoma).
  • During a median follow up of 5 years all patients with primary testicular tumours survived event free.
  • Meta-analysis of the recent literature revealed that testis sparing surgery is feasible and save in prepubertal boys after exclusion of a malignant tumour.
  • If a testis sparing approach is planned, the following criteria are essential: 1.
  • The presence of a well defined circumscribed nodule confirmed by imaging.
  • 3. The presence of sufficient healthy testicular parenchyma.
  • However, the high rate of malignant or potentially malignant tumours suggests that high inguinal orchidectomy should remain the surgical standard of therapy.
  • [MeSH-major] Granulosa Cell Tumor / surgery. Leydig Cell Tumor / surgery. Neoplasms, Germ Cell and Embryonal / surgery. Sertoli Cell Tumor / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Diagnostic Imaging. Feasibility Studies. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Orchiectomy / methods. Retrospective Studies. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525908.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


18. Ross JH, Rybicki L, Kay R: Clinical behavior and a contemporary management algorithm for prepubertal testis tumors: a summary of the Prepubertal Testis Tumor Registry. J Urol; 2002 Oct;168(4 Pt 2):1675-8; discussion 1678-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical behavior and a contemporary management algorithm for prepubertal testis tumors: a summary of the Prepubertal Testis Tumor Registry.
  • PURPOSE: The Prepubertal Testis Tumor Registry was established by the Urologic Section of the American Academy of Pediatrics in 1980 to record data on a large number of prepubertal testis tumors regarding presentation, treatment and outcome to define appropriate management better.
  • We reviewed the registry data in the context of other modern studies to elucidate the appropriate management of these rare tumors.
  • MATERIALS AND METHODS: Relevant data in the prepubertal testis tumor registry were tabulated and analyzed.
  • RESULTS: There were 395 prepubertal patients who had a primary testis tumor.
  • Generally benign tumors accounted for 38% of cases.
  • A significant proportion of tumors were benign regardless of patient age. alpha-Fetoprotein levels for patients with benign and malignant tumors overlapped in children younger than 6 months.
  • Of the patients with yolk sac tumor 80% presented with stage 1 disease and overall survival was excellent.
  • Of all patients with stromal tumors metastases developed in only 1.
  • CONCLUSIONS: We recommend initial excisional biopsy for all amenable prepubertal testis tumors, except those with an alpha-fetoprotein level that is clearly increased for patient age.
  • Patients with benign tumors may be released from oncological followup.
  • Patients with stage I yolk sac tumor should be monitored closely, and those with recurrent or metastatic yolk sac tumor should be treated with chemotherapy.
  • Retroperitoneal lymph node dissection is reserved for patients with recurrent retroperitoneal masses following chemotherapy.
  • Aggressive treatment of metastatic Sertoli cell or undifferentiated stromal tumors is warranted.
  • [MeSH-major] Registries / statistics & numerical data. Testicular Neoplasms / congenital
  • [MeSH-minor] Algorithms. Child. Child, Preschool. Combined Modality Therapy. Endodermal Sinus Tumor / congenital. Endodermal Sinus Tumor / mortality. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Humans. Infant. Male. Neoplasm Staging. Prognosis. Sertoli Cell Tumor / congenital. Sertoli Cell Tumor / mortality. Sertoli Cell Tumor / pathology. Sertoli Cell Tumor / therapy. Sex Cord-Gonadal Stromal Tumors / congenital. Sex Cord-Gonadal Stromal Tumors / mortality. Sex Cord-Gonadal Stromal Tumors / pathology. Sex Cord-Gonadal Stromal Tumors / therapy. Survival Rate. United States. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12352332.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


19. Mikuz G: [WHO classification of testicular tumors]. Verh Dtsch Ges Pathol; 2002;86:67-75
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [WHO classification of testicular tumors].
  • [Transliterated title] WHO-Klassifikation der Hodentumoren.
  • Twenty years after the first edition (1977), the WHO has presented the updated version of the "Histological typing of testis tumours".
  • The most important is obviously the precursor lesion of germ cell tumors, which has been called "intratubular malignant germ cells".
  • Such atypical cells appear in the tubules adjacent to the germ cell tumors, in some few cases (6%) also in the contra lateral healthy gonad and rarely in infertile men (1%).
  • The precursor lesion can progress to franc germ cell tumor starting probably with seminoma, which still maintain the capability of differentiation (pluripotente cells) in all other types of non-seminomatous germ cell tumors.
  • This lesion is missed in germ cell tumors of childhood and in spermatocytic seminomas, both seem to have a histogenetic history rather different from the other germ cell in adults.
  • Most of the new diagnoses are subtypes--called "variants"--of well known tumors.
  • Spermatocytic seminomas are perfectly benign tumors but they become a life threatening disease when combined with sarcomas (new entity).
  • This is a harmless name for an extremely dangerous tumor in which one tissue overgrows the other and gives rise to somatic type sarcomas or carcinomas.
  • Such tumors do not respond like germ cell tumors to the usual chemotherapy.
  • Treatment should be tailored according to that used in standard management of the respective sarcoma or carcinoma.
  • In the comments it is mentioned that the testis carcinoid could be a part of teratoma, but the diagnosis is listed in the group of "miscellaneous" tumors together with tumors of ovarian epithelial type.
  • This is a very questionable decision because the normal testis does not contain neuroendocrine cells from which carcinoids would have to be able to develop.
  • "Large cell calcifying Sertoli cell tumour" has been recently described and can be sporadic or inherited.
  • This morphologically peculiar tumor can be part of the Swiss syndrome also called Carney's complex.
  • The patients have cardiac myxomas, spotty skin pigmentation, hormone active nodular hyperplasia of the adrenals and soft tissue myxomas.
  • The newly appearing "mixed germ cell--sex cord/gonadal stromal tumours, unclassified" has a histology similar to the well known gonadoblastomas.
  • In contrast to gonadoblastoma, however, these tumors occur in testes of genotypic and phenotypic normal males.
  • For the therapy of germ cell tumor an assessment of risk factors found by the pathologists is extremely important.
  • The most important independent predictors of relapse are tumor invasion of blood or lymph-vessels, absence of yolk sac elements and the presence of an embryonal carcinoma component.
  • In the absence of such predictors a surveillance policy allows some patients to forgo chemotherapy.
  • [MeSH-major] Testicular Neoplasms / classification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12647353.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


20. Schneider DT, Calaminus G, Wessalowski R, Pathmanathan R, Harms D, Göbel U: Therapy of advanced ovarian juvenile granulosa cell tumors. Klin Padiatr; 2002 Jul-Aug;214(4):173-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy of advanced ovarian juvenile granulosa cell tumors.
  • BACKGROUND: Gonadal sex cord-stromal tumors are rare tumors that develop from the gonadal non-germ cell component such as granulosa, Sertoli or Leydig cells.
  • Among these, juvenile granulosa cell tumors (JGCT) constitute the largest subgroup of ovarian sex cord-stromal tumors during childhood and adolescence.
  • In local disease (FIGO stage I), the beneficial role of tumor-ovarectomy is well established.
  • In contrast, life expectancy in patients with advanced JGCT (FIGO stage >/= II) is short even after complete tumor resection.
  • The current literature provides only limited and inconclusive data regarding the value of adjuvant chemotherapy in such patients with advanced disease.
  • PATIENTS AND METHODS: Therefore, we analyzed the patients with FIGO stage >/= II JGCT who were prospectively documented as follow-up patients of the German MAKEI trials for non-testicular germ cell tumors and received the recommended cisplatin-based chemotherapy in an adjuvant setting.
  • Two patients received laparoscopic tumor resection, which was incomplete in both.
  • All patients received 4 or 6 cycles of adjuvant cisplatin-based three-agent chemotherapy in analogy to the current therapeutic concept applied in malignant germ cell tumors.
  • One patient with a large tumor and multiple peritoneal metastases additionally received 40 Gy abdominal irradiation.
  • RESULTS: All patients achieved complete clinical remission after initial surgery and adjuvant chemotherapy.
  • One patient developed a metachronous tumor of the contralateral ovary after 126 months follow-up and is still alive but currently in therapy of another recurrence.
  • Another patient suffered a tumor recurrence after 12 months but achieved a second complete remission with cisplatin chemotherapy after a follow-up of currently 4 months.
  • One patient achieved complete clinical remission but suffered a diffuse peritoneal tumor recurrence with massive ascites and finally died as a result of tumor progression.
  • In summary, at the time of this report 6 of 7 patients are alive after a median of 47 (15 - 138) months.
  • CONCLUSION: This analysis clearly demonstrates that advanced JGCT can be successfully treated with surgery followed by adjuvant cisplatin-based chemotherapy.
  • Therefore, this study reveals encouraging therapeutic perspectives in these otherwise fatal tumors that merit further investigation in a prospective cooperative trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulosa Cell Tumor / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Female. Follow-Up Studies. Germany. Humans. Neoplasm Staging. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12165898.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Iwamoto I, Yanazume S, Fujino T, Yoshioka T, Douchi T: Leydig cell tumor in an elderly patient with complete androgen insensitivity syndrome. Gynecol Oncol; 2005 Mar;96(3):870-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leydig cell tumor in an elderly patient with complete androgen insensitivity syndrome.
  • Testicular tumors often develop in patients with AIS, Sertoli cell tumor and seminoma being the most common types.
  • Leydig cell tumor in AIS is extremely rare.
  • CASE: A large abdominal tumor developed in a 73-year-old female patient.
  • The patient underwent the extirpation of bilateral gonads including the tumor, pelvic lymph nodes, omentum and appendix vermiformis.
  • The pathological diagnosis was malignant Leydig cell tumor of the left testis.
  • There was no adjuvant radiation or chemotherapy performed.
  • CONCLUSION: We reported an extremely rare case of malignant Leydig cell tumor developing in an elderly AIS patient.
  • [MeSH-major] Androgen-Insensitivity Syndrome / complications. Leydig Cell Tumor / complications. Ovarian Neoplasms / complications


22. Cecchetto G, Alaggio R, Bisogno G, Virgone C, Dall'Igna P, Terenziani M, Boldrini R, D'Onofrio V, Ferrari A, Bernini G: Sex cord-stromal tumors of the testis in children. A clinicopathologic report from the Italian TREP project. J Pediatr Surg; 2010 Sep;45(9):1868-73
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex cord-stromal tumors of the testis in children. A clinicopathologic report from the Italian TREP project.
  • PURPOSE: Testicular sex cord-stromal tumors (SCSTs) are very rare in children and include a variety of neoplasms with different clinical features and biologic behavior.
  • Aim of the study was to report the clinical findings and results observed in a series of patients with testicular SCST, registered in a multi-institutional Italian network on rare tumors in children and adolescents.
  • Chemotherapy was recommended in patients with incomplete surgery or metastatic disease.
  • RESULTS: A testicular mass was the most common symptom.
  • All patients underwent primary removal of the tumor; orchiectomy with high ligation of spermatic cord was performed in 7 and tumor enucleation in 4.
  • At histology, 4 patients had Leydig cell tumors, 4 juvenile granulosa cell tumors, 1 Sertoli cell tumor, 1 incompletely differentiated SCST, and 1 SCST with an intermediate pattern Sertoli cell tumor/mixed form.
  • CONCLUSIONS: Our experience confirmed the rarity of testicular SCST.
  • They have to be considered in the differential diagnosis of testicular solid masses, taking into account that hormonal signs are present in a minority of cases.
  • [MeSH-major] Sex Cord-Gonadal Stromal Tumors / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Humans. Infant. Italy. Male. Orchiectomy. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20850634.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. La Marca A, Volpe A: The Anti-Mullerian hormone and ovarian cancer. Hum Reprod Update; 2007 May-Jun;13(3):265-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Anti-Mullerian hormone (AMH), which is produced by fetal Sertoli cells, is responsible for regression of Mullerian ducts, the anlagen for uterus and Fallopian tubes, during male sex differentiation.
  • The patterns of expression of AMH and its type II receptor in the post-natal ovary indicate that AMH may play an important role in ovarian folliculogenesis.
  • Recent advances in the physiological role of AMH has stimulated interest in the significance of AMH as a diagnostic marker and therapeutic agent for ovarian cancer.
  • Currently, AMH has been shown to be a circulating marker specifically for granulosa cell tumour (GCT).
  • Its diagnostic performance seems to be very good, with a sensitivity ranging between 76 and 93%.
  • Based on the physiological inhibitory role of AMH in the Mullerian ducts, it has been proposed that AMH may inhibit epithelial ovarian cancer cell both in vitro and in vivo.
  • These observations will be the basis for future research aiming to investigate the possible clinical role of AMH as neo-adjuvant, or most probably adjuvant, therapy for ovarian cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Glycoproteins / physiology. Glycoproteins / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / physiopathology. Testicular Hormones / physiology. Testicular Hormones / therapeutic use
  • [MeSH-minor] Anti-Mullerian Hormone. Biomarkers, Tumor / blood. Female. Humans

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17213257.001).
  • [ISSN] 1355-4786
  • [Journal-full-title] Human reproduction update
  • [ISO-abbreviation] Hum. Reprod. Update
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Testicular Hormones; 80497-65-0 / Anti-Mullerian Hormone
  • [Number-of-references] 61
  •  go-up   go-down






Advertisement